Plasmid-DNA vaccines encoding neoantigens, typically delivered by electroporation — the platform behind Geneos' and several academic programs.
Geneos Therapeutics, Wistar, and collaborators translate personalized DNA vaccine technology into clinical outcome based on mistakes tumors make image: Dr. David Weiner, EVP of The Wistar Institute PHILADELPHIA — (Tuesday, April 30, 2024) — Hepatocellular carcinoma (H…
[RECRUITING · PHASE2 · Geneos Therapeutics] This is a randomized, open-label, multi-site Phase II study of a personalized neoantigen DNA vaccine (GNOS-PV02) and plasmid encoded IL-12 (INO-9012) in subjects with histologically or cytologically confirmed diagnosis of HCC based on p…
Geneos Therapeutics has launched a randomized, open-label Phase II study (NCT07722741) for GNOS-PV02, a personalized neoantigen DNA vaccine combined with plasmid-encoded IL-12 (INO-9012). The trial targets patients with high-risk hepatocellular carcinoma (HCC) who are disease-free post-resection, aiming to prevent recurrence. This marks a significant clinical step for Geneos in validating its DNA-based platform in a adjuvant setting.
A study on plasmid DNA electroporation for neoantigen vaccines reveals that the technique sequesters activated CD8+ T cells in the treated muscle tissue rather than promoting tumor infiltration. While the method induces strong local immune gene activation, flow cytometry showed neoantigen-specific T cells accumulating at the vaccination site instead of the tumor. This suggests that electroporation-induced tissue remodeling may limit therapeutic efficacy by trapping effector cells away from the cancer.